Pacira Pharmaceuticals Inc (PCRX)
$23.64
$-0.05
(-0.21%)
As on 07-May-2026 16:00EDT
Market cap
$932 Mln
Revenue (TTM)
$735 Mln
P/E Ratio
182.2
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
26.31
-
EV/EBITDA
10
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
39,322,924
10 Years Aggregate
CFO
$727.77 Mln
EBITDA
$521.17 Mln
Net Profit
$141.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pacira Pharmaceuticals Inc (PCRX)
| -8.7 | 6.2 | 16.1 | -6.0 | -18.0 | -17.9 | -6.7 |
|
BSE Sensex*
| -8.6 | 3.8 | -7.4 | -4.1 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Pacira Pharmaceuticals Inc (PCRX)
| 37.4 | -43.9 | -12.6 | -35.8 | 0.6 | 32.1 | 5.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pacira Pharmaceuticals Inc (PCRX)
|
23.6 | 932.2 | 734.9 | 9.3 | 2.6 | 1.3 | 182.2 | 1.5 |
| 13.7 | 4,344.8 | 2,323.3 | 137.9 | 12.3 | -- | 61.9 | 105.4 | |
| 15.1 | 201.2 | 116.3 | -11.1 | -10.5 | -7.9 | -- | 1.5 | |
| 0.5 | 21.4 | 4.2 | -3.6 | -55.0 | -0 | -- | 0.9 | |
| 51.1 | 5,598.4 | 769.1 | 47.9 | 5.4 | 7.5 | 149 | 8.6 | |
| 9.1 | 469.5 | 676.8 | -15.4 | 9.0 | -- | -- | 0.8 | |
| 3.1 | 1,150.8 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.4 | |
| 8.1 | 5,723.6 | 7,682.7 | 438.7 | 15.9 | 7.5 | 12.2 | 0.9 | |
| 0.1 | 107.0 | 0.0 | -17.4 | -- | -- | -- | 14.4 | |
| 26.7 | 1,420.7 | 61.4 | -166.2 | -267.6 | -- | -- | 49.0 |
Shareholding Pattern
View DetailsAbout Pacira Pharmaceuticals Inc (PCRX)
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a... bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California. Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 Read more
-
Chief Financial Officer
Mr. Charles A. Reinhart III, CPA, M.B.A.
-
Chief Financial Officer
Mr. Charles A. Reinhart III, CPA, M.B.A.
-
Headquarters
Brisbane, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pacira Pharmaceuticals Inc (PCRX)
What is the current share price of Pacira Pharmaceuticals Inc (PCRX) Today?
The share price of Pacira Pharmaceuticals Inc (PCRX) is $23.64 (NASDAQ) as of 07-May-2026 16:00 EDT. Pacira Pharmaceuticals Inc (PCRX) has given a return of -18.01% in the last 3 years.
What is the current PB & PE ratio of Pacira Pharmaceuticals Inc (PCRX)?
The P/E ratio of Pacira Pharmaceuticals Inc (PCRX) is 182.23 times as on 07-May-2026, a 593 premium to its peers’ median range of 26.31 times.
The P/B ratio of Pacira Pharmaceuticals Inc (PCRX) is 1.49 times as on 07-May-2026, a 74 discount to its peers’ median range of 5.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
158.14
|
1.60
|
|
2024
|
-9.28
|
1.19
|
|
2023
|
41.87
|
2.02
|
|
2022
|
111.35
|
2.29
|
|
2021
|
63.92
|
3.67
|
What is the 52 Week High and Low of Pacira Pharmaceuticals Inc (PCRX)?
The 52-week high and low of Pacira Pharmaceuticals Inc (PCRX) are Rs 27.64 and Rs 18.92 as of 08-May-2026.
What is the market cap of Pacira Pharmaceuticals Inc (PCRX)?
Pacira Pharmaceuticals Inc (PCRX) has a market capitalisation of $ 932 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pacira Pharmaceuticals Inc (PCRX)?
Before investing in Pacira Pharmaceuticals Inc (PCRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.